Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
News & Featured Media
10 – 12 June, 2025 | Congress Center, Basel Switzerland
Antibody Engineering & Therapeutics Europe
Dr. Sai Reddy, scientific co-founder of Encelta, delivered a keynote at the 2024 Antibody Engineering & Therapeutics Europe conference in Basel. His talk focused on innovations in T cell engineering and the emerging synergy between bispecific antibodies and cell-based therapies.
Encelta: The Venture Leader Biotech revolutionizing cell therapy
Venture Lab: Encelta was selected for Venture Leaders Biotech, a program spotlighting Switzerland’s most promising biotech startups with global potential.
Encelta featured in Swiss Startup Radar
Swiss.ch: Encelta was selected for the prestigious Venture Leaders Biotech program, positioning it among Switzerland’s most promising early-stage biotech startups.
ETH Zurich News Feature
ETH Zurich: ETH Zurich published a profile on Encelta’s patented TCR engineering strategy, describing it as a major advance in synthetic immunology.
Spark Award 2023 - Enhancing bispecific antibody therapies with healthy donor T cells
YouTube Video: Encelta’s foundational technology was named a top 5 finalist for ETH Zurich’s Spark Award.
The Medicine Maker: T Cell Bright Spark
The Medicine Maker: Spotlight Encelta’s platform as one of the brightest emerging technologies in cell therapy.
Publications
Featured on cover!
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
Encelta’s foundational research was published in Nature Biomedical Engineering and featured on the cover of Volume 8, Issue 12. This cover recognition reflects both the scientific rigor and therapeutic relevance of the work, placing Encelta’s innovation at the forefront of synthetic immunology.
